| Literature DB >> 23118878 |
Chun-Yi Chuang1, Wen-Wei Sung, Lee Wang, Wea-Long Lin, Kun-Tu Yeh, Mao-Chang Su, Chun-Han Hsin, Shiann-Yann Lee, Buor-Chang Wu, Ya-Wen Cheng, Huei Lee.
Abstract
Human papillomavirus (HPV) is a risk factor in a subset of oropharyngeal cancer; however, the contribution of HPV in the malignancy of oral squamous cell carcinomas (OSCC) is not fully understood in Taiwanese. Herein, 61 patients with no risk factors and 117 patients with one or more risk factors were enrolled in this study. HPV16/18 infection rate in non-smokers, non-drinkers and non-betel quid chewers was higher than their counterparts. The development of HPV-infected cancer has been shown to be associated with interleukin-10 (IL-10) expression. To this end, IL-10 mRNA expression in OSCC tumors was evaluated by real-time RT-PCR. Data showed that HPV-positive patients had higher IL-10 mRNA levels than in HPV-negative patients. Kaplan-Meier and Cox-regression analysis indicated that the prognostic significance of IL-10 mRNA on overall survival and relapse free survival was only observed in HPV-positive OSCC, but not in HPV-negative OSCC. Mechanistically, the elevation of IL-10 by E6 was responsible for increased colony formation and migration capability in OSCC cells. Therefore, we suggest that IL-10 induced by E6 promotes cell growth and migration capability and consequent poor survival and relapse in HPV-positive OSCC.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23118878 PMCID: PMC3485273 DOI: 10.1371/journal.pone.0047541
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Relationships between HPV16, HPV18 and HPV16/18 infection and clinical parameters in OSCC patients.
| Parameters | Case No. | HPV 16 | HPV 18 | HPV 16/18 |
| Age | ||||
| <56 | 105 | 30 (28.6) | 30 (28.6) | 50 (47.6) |
| ≥56 | 73 | 24 (32.9) | 24 (32.9) | 44 (60.3) |
| Gender | ||||
| Female | 70 | 34 (48.6) | 31 (44.3) | 56 (80.0) |
| Male | 108 | 20 (18.5) | 23 (21.3) | 38 (35.2) |
| Smoking | ||||
| No | 73 | 33 (45.2) | 30 (41.1) | 53 (72.6) |
| Yes | 105 | 21 (20.0) | 24 (22.9) | 41 (39.0) |
| Drinking | ||||
| No | 99 | 35 (35.4) | 39 (39.4) | 64 (64.6) |
| Yes | 79 | 19 (24.1) | 15 (19.0) | 30 (38.0) |
| Betel quid | ||||
| No | 80 | 33 (41.3) | 36 (45.0) | 60 (75.0) |
| Yes | 98 | 21 (21.4) | 18 (18.4) | 34 (34.7) |
| Stage | ||||
| I+II | 103 | 31 (30.1) | 26 (25.2) | 50 (48.5) |
| III+IV | 75 | 23 (30.7) | 28 (37.3) | 44 (58.7) |
| T value | ||||
| T1+T2 | 135 | 40 (29.6) | 40 (29.6) | 69 (51.1) |
| T3+T4 | 43 | 14 (32.6) | 14 (32.6) | 25 (58.1) |
| N value | ||||
| N0 | 128 | 39 (30.5) | 34 (26.6) | 64 (50.0) |
| N1+N2 | 50 | 15 (30.0) | 20 (40.0) | 30 (60.0) |
| Tumor site | ||||
| Tongue | 92 | 35 (38.0) | 35 (38.0) | 60 (65.2) |
| Buccal | 68 | 17 (25.0) | 15 (22.1) | 28 (41.2) |
| Other | 18 | 2 (11.1) | 4 (22.2) | 6 (33.3) |
| IL10 | ||||
| Low | 89 | 18 (20.2) | 21 (23.6) | 34 (38.2) |
| High | 89 | 36 (40.4) | 33 (37.1) | 60 (67.4) |
Other tumor sites includes plate (n = 1), gingival (n = 8), and lip (n = 9).
p<0.05;
p = 0.05.
Comparison of IL-10 mRNA expression levels between HPV-positive and HPV–negative OSCC patients.
| IL-10 mRNA | |||||
| HPV type | Case No. | Low (%) | High (%) | Odds Ratio (95% CI) | P value |
| HPV 16 | |||||
| Negative | 124 | 71 (57.3) | 53 (42.7) | Referent | |
| Positive | 54 | 18 (33.3) | 36 (66.7) | 2.679 (1.373–5.227) | 0.003 |
| HPV 18 | |||||
| Negative | 124 | 68 (54.8) | 56 (45.2) | Referent | |
| Positive | 54 | 21 (38.9) | 33 (61.1) | 1.908 (0.995–3.661) | 0.050 |
| HPV 16/18 | |||||
| Negative | 84 | 55 (65.5) | 29 (34.5) | Referent | |
| Positive | 94 | 34 (36.2) | 60 (63.8) | 3.347 (1.808–6.196) | <0.001 |
Fourteen of 178 patients had both HPV16 and 18 infections.
IL-10 low: 0.6±0.8 (0.0–2.38); IL-10 high: 237.0±413.5 (2.39–1402.2).
Figure 1Kaplan-Meier analysis was used to assess the influence of IL-10 on OS and RFS.
(A) in all study population, (B) in patients with HPV 16/18 infection compared to those without HPV 16/18 infection, (C) in patients with HPV 16/18 non-infection, and (D) in patients with HPV16/18 infection.
Multivariate analysis of the influence of HPV 16/18 expression and IL-10 mRNA expression on overall survival (OS) and relapse free survival (RFS) in oral cancer patients.
| Parameter | Case No. | OS | RFS | ||||||
| 5-year survival (%) | HR | 95% CI | P | 5-year survival (%) | HR | 95%CI | P | ||
|
| |||||||||
| Low | 89 | 67.4 | 1.000 | Referent | 45.7 | 1.000 | Referent | ||
| High | 89 | 47.2 | 2.438 | 1.345–4.419 | 0.003 | 29.9 | 2.098 | 1.329–3.311 | 0.001 |
|
| |||||||||
| Negative | 84 | 72.6 | 1.000 | Referent | 49.2 | 1.000 | Referent | ||
| Positive | 94 | 46.3 | 1.765 | 0.790–3.945 | 0.166 | 27.2 | 1.604 | 0.847–3.038 | 0.147 |
|
| |||||||||
| IL-10 Low | 55 | 68.4 | 1.000 | Referent | 48.0 | 1.000 | Referent | ||
| IL-10 High | 29 | 68.7 | 1.323 | 0.521–3.361 | 0.556 | 53.1 | 1.237 | 0.610–2.507 | 0.555 |
|
| |||||||||
| IL-10 Low | 34 | 70.8 | 1.000 | Referent | 47.0 | 1.000 | Referent | ||
| IL-10 High | 60 | 28.7 | 4.810 | 1.946–11.892 | 0.001 | 0.0 | 3.807 | 1.771–8.184 | 0.001 |
The interaction between HPV and IL-10: χ2 = 2.675, df = 1, P = 0.102 for OS; χ2 = 2.781, df = 1, P = 0.095 for RFS.
Multivariate analysis of the influence of various parameters on overall survival (OS) and relapse free survival (RFS) in oral cancer patients according to gender.
| Parameter | Category | Case No. | OS | RFS | ||||||
| 5-year survival (%) | HR | 95% CI | P | 5-year survival (%) | HR | 95%CI | P | |||
|
| ||||||||||
| Stage | III+IV/I+II | 25/45 | 36.3/72.0 | 3.393 | 1.389–8.289 | 0.007 | 10.6/58.3 | 2.844 | 1.441–5.614 | 0.003 |
| HPV | Positive/Negative | 56/14 | 51.9/83.9 | 1.715 | 0.484–6.081 | 0.404 | 26.9/84.6 | 3.764 | 1.111–12.749 | 0.033 |
| IL-10 | High/Low | 38/32 | 24.5/76.3 | 3.610 | 1.345–9.689 | 0.011 | 0.0/65.0 | 9.258 | 3.272–26.196 | <0.001 |
|
| ||||||||||
| Stage | III+IV/I+II | 50/58 | 22.7/81.9 | 3.707 | 1.622–8.471 | 0.002 | 0.0/60.3 | 4.017 | 2.112–7.641 | <0.001 |
| HPV | Positive/Negative | 38/70 | 52.3/62.2 | 1.170 | 0.553–2.475 | 0.682 | 32.3/37.5 | 1.020 | 0.563–1.847 | 0.948 |
| IL-10 | High/Low | 51/57 | 60.5/60.4 | 2.140 | 1.002–4.571 | 0.049 | 51.5/30.7 | 1.309 | 0.741–2.314 | 0.354 |
|
| ||||||||||
| Stage | III+IV/I+II | 24/49 | 35.8/74.0 | 2.791 | 1.108–7.031 | 0.029 | 5.9/58.5 | 2.459 | 1.200–5.036 | 0.014 |
| HPV | Positive/Negative | 53/20 | 53.8/77.9 | 0.732 | 0.213–2.517 | 0.620 | 27.9/63.8 | 0.988 | 0.376–2.596 | 0.981 |
| IL-10 | High/Low | 39/34 | 32.1/75.9 | 3.121 | 1.011–9.635 | 0.048 | 0.0/60.6 | 5.894 | 2.081–16.695 | 0.001 |
|
| ||||||||||
| Stage | III+IV/I+II | 51/54 | 30.2/81.8 | 3.953 | 1.671–9.351 | 0.002 | 10.9/69.2 | 3.460 | 1.816–6.592 | <0.001 |
| HPV | Positive/Negative | 64/41 | 50.0/71.1 | 1.279 | 0.595–2.748 | 0.528 | 31.1/51.9 | 1.121 | 0.612–2.052 | 0.712 |
| IL-10 | High/Low | 50/55 | 56.1/55.1 | 2.497 | 1.160–5.373 | 0.019 | 46.8/31.9 | 1.428 | 0.803–2.539 | 0.225 |
|
| ||||||||||
| Stage | III+IV/I+II | 38/61 | 39.8/78.9 | 4.206 | 1.828–9.679 | 0.001 | 13.8/66.9 | 3.692 | 1.994–6.841 | <0.001 |
| HPV | Positive/Negative | 64/35 | 55.9/77.1 | 1.335 | 0.480–3.711 | 0.579 | 33.6/61.5 | 1.290 | 0.614–2.710 | 0.502 |
| IL-10 | High/Low | 47/52 | 45.5/75.9 | 2.995 | 1.292–6.939 | 0.011 | 23.5/59.0 | 2.643 | 1.389–5.029 | 0.003 |
|
| ||||||||||
| Stage | III+IV/I+II | 37/42 | 21.9/76.4 | 2.902 | 1.178–7.151 | 0.021 | 0.0/33.1 | 2.952 | 1.434–6.075 | 0.003 |
| HPV | Positive/Negative | 30/49 | 57.4/53.1 | 1.083 | 0.437–2.686 | 0.864 | 12.8/18.1 | 1.252 | 0.608–2.578 | 0.542 |
| IL-10 | High/Low | 42/37 | 52.7/48.7 | 1.760 | 0.721–4.297 | 0.215 | 41.4/13.5 | 1.397 | 0.696–2.806 | 0.347 |
|
| ||||||||||
| Stage | III+IV/I+II | 34/46 | 34.3/64.2 | 3.523 | 1.446–8.583 | 0.006 | 11.0/64.7 | 2.911 | 1.456–5.818 | 0.003 |
| HPV | Positive/Negative | 60/20 | 51.3/68.0 | 0.598 | 0.192–1.864 | 0.376 | 27.3/70.9 | 1.238 | 0.459–3.341 | 0.673 |
| IL-10 | High/Low | 40/40 | 25.9/70.2 | 5.395 | 1.886–15.431 | 0.002 | 0.0/58.1 | 7.002 | 2.640–18.571 | <0.001 |
|
| ||||||||||
| Stage | III+IV/I+II | 41/57 | 27.3/81.6 | 3.118 | 1.322–7.356 | 0.009 | 0.0/54.6 | 3.459 | 1.819–6.579 | <0.001 |
| HPV | Positive/Negative | 34/64 | 60.4/63.8 | 1.274 | 0.552–2.942 | 0.570 | 41.2/35.7 | 1.160 | 0.609–2.212 | 0.650 |
| IL-10 | High/Low | 49/49 | 61.6/64.9 | 1.871 | 0.815–5.296 | 0.140 | 48.2/30.8 | 1.075 | 0.582–1.986 | 0.816 |
Figure 2IL-10 expression increases associated with HPV16/18 E6 is responsible for the migration capability of OSCC cell lines.
(A) IL-10 expression in a panel of OSCC cell lines was evaluated by Western blotting; (B) GNM cells were knocked down by transfection of shHPV18 E6 and Tw2.6 cells were transiently transfected with HPV16 E6 cDNA plasmid for 48 hrs. β-actin was used as a protein loading control; (C) GNM cells were knocked down by transfection of shIL-10. Tw2.6 and SCC25 cells were co-transfected with HPV16 E6 cDNA plasmid, and then E6 and IL-10 expression were determined by Western blotting. β-actin was used as a protein loading control; (D) The migration and colony formation capability of GNM cells with or without transfection of shIL-10 was evaluated by transwell migration assay; and (E) E6 transfected-Tw2.6 and -SCC25 cells were co-transfected with two doses of shIL-10, and then the migration and colony formation capability of both cells was evaluated by transwell migration assay.